These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38219820)

  • 21. The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways.
    Fisher EA
    Biochim Biophys Acta; 2012 May; 1821(5):778-81. PubMed ID: 22342675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State.
    Tikkanen E; Minicocci I; Hällfors J; Di Costanzo A; D'Erasmo L; Poggiogalle E; Donini LM; Würtz P; Jauhiainen M; Olkkonen VM; Arca M
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):665-674. PubMed ID: 30816800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.
    Johnson LA; Altenburg MK; Walzem RL; Scanga LT; Maeda N
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1745-52. PubMed ID: 18617647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.
    Shimizugawa T; Ono M; Shimamura M; Yoshida K; Ando Y; Koishi R; Ueda K; Inaba T; Minekura H; Kohama T; Furukawa H
    J Biol Chem; 2002 Sep; 277(37):33742-8. PubMed ID: 12097324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation.
    Tikka A; Soronen J; Laurila PP; Metso J; Ehnholm C; Jauhiainen M
    Biosci Rep; 2014 Dec; 34(6):e00160. PubMed ID: 25495645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.
    Chen YQ; Pottanat TG; Zhen EY; Siegel RW; Ehsani M; Qian YW; Konrad RJ
    J Lipid Res; 2021; 62():100068. PubMed ID: 33762177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.
    Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H
    J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
    J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ANGPTL3 as therapeutic target.
    Kersten S
    Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.
    Robciuc MR; Maranghi M; Lahikainen A; Rader D; Bensadoun A; Öörni K; Metso J; Minicocci I; Ciociola E; Ceci F; Montali A; Arca M; Ehnholm C; Jauhiainen M
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1706-13. PubMed ID: 23661675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
    Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
    Eur J Prev Cardiol; 2024 Aug; 31(10):1216-1223. PubMed ID: 38484368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis.
    Pan M; Liang Js JS; Fisher EA; Ginsberg HN
    J Biol Chem; 2002 Feb; 277(6):4413-21. PubMed ID: 11704664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4.
    Wang B; Shen Y; Zhai L; Xia X; Gu HM; Wang M; Zhao Y; Chang X; Alabi A; Xing S; Deng S; Liu B; Wang G; Qin S; Zhang DW
    J Lipid Res; 2021; 62():100091. PubMed ID: 34118252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
    Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
    JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
    Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.
    Landfors F; Chorell E; Kersten S
    J Lipid Res; 2023 Jan; 64(1):100313. PubMed ID: 36372100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiopoietin-like 3 in lipoprotein metabolism.
    Kersten S
    Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.